Masitinib

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs.[1][2] Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, and amyotrophic lateral sclerosis.[3][4]

Masitinib

Clinical data
Trade names	Masivet, Kinavet
AHFS/Drugs.com	International Drug Names
ATC code	L01EX06 (WHO)
Identifiers
IUPAC name 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide
CAS Number	790299-79-5
PubChem CID	10074640
ChemSpider	8250179
UNII	M59NC4E26P
KEGG	D10229
ChEMBL	ChEMBL1908391
PDB ligand	G65 (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID001000207
Chemical and physical data
Formula	C28H30N6OS
Molar mass	498.65 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O=C(c1ccc(cc1)CN2CCN(C)CC2)Nc3cc(c(cc3)C)Nc4nc(cs4)c5cccnc5
InChI InChI=InChI=1S/C28H30N6OSc1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32) Key:WJEOLQLKVOPQFV-UHFFFAOYSA-N

Mechanism of action

Masitinib is a tyrosine kinase inhibitor which inhibits tyrosine kinases, enzymes responsible for the activation of many proteins by signal transduction cascades. Specifically, masitinib targets the receptor tyrosine kinase c-Kit which is found to be overexpressed or mutated in several types of cancer.[2][5] Masitinib is also additional targets, it also inhibits the platelet derived growth factor receptor (PDGFR), lymphocyte-specific protein tyrosine kinase (Lck), focal adhesion kinase (FAK) and fibroblast growth factor receptor 3 (FGFR3) as well as CSF1R.[6] [7]

Clinical Use

Masitinib was under investigation for the treatment of systemic mastocytosis (Masipro) but approval was denied in the EU in 2017 due to concerns "about the reliability of the study results" and major changes to the study design.[8][9]

European approval of masitinib for treatment of amyotrophic lateral sclerosis (Alsitek) was also refused in 2018.[10]

References

1. Hahn KA, Ogilvie G, Oglivie G, Rusk T, Devauchelle P, Leblanc A, et al. (2008). "Masitinib is safe and effective for the treatment of canine mast cell tumors". Journal of Veterinary Internal Medicine. 22 (6): 1301–9. doi:10.1111/j.1939-1676.2008.0190.x. PMID 18823406.
2. Information about Masivet at the European pharmacy agency website
3. "Orphan designation EU/3/16/1722 for masitinib mesilate for the treatment of amyotrophic lateral sclerosis". European Medicines Agency. 2018-09-17.
4. Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, et al. (June 2015). "Masitinib for the treatment of mild to moderate Alzheimer's disease". Expert Review of Neurotherapeutics. 15 (6): 587–96. doi:10.1586/14737175.2015.1045419. PMID 25961655. S2CID 39839943.
5. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007258
6. Gil da Costa RM (July 2015). "C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic". Veterinary Journal. 205 (1): 5–10. doi:10.1016/j.tvjl.2015.05.002. PMID 26021891.
7. https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0620-9
8. Refusal of the marketing authorisation for Masipro (masitinib). (PDF) EMA, 15. September 2017; abgerufen am 21. September 2017
9. https://ec.europa.eu/health/documents/community-register/html/ho26274.htm
10. https://ec.europa.eu/health/documents/community-register/html/ho26580.htm